...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gynecologic Oncology Reports >Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits
【24h】

Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits

机译：在复发性或进行性宫颈癌中重复使用铂/贝伐单抗可产生边缘生存获益

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Our objective was to assess overall survival of cervical cancer patients following prior platinum/bevacizumab chemotherapy, comparing retreatment with platinum/bevacizumab with alternative therapies. A retrospective analysis was performed of women who received platinum/bevacizumab (PB) chemotherapy for cervical cancer at Washington University between July 1, 2005 and December 31, 2015. Wilcoxon rank-sum exact test and Fisher's exact test were used to compare the treatment groups, and Kaplan Meier curves were generated. Cox regression analyses were performed, with treatment free interval and prior therapy response included as covariates. Of 84 patients who received PB chemotherapy, 59 (70%) received no second line chemotherapy, as they did not recur, progressed without further chemotherapy, were lost to follow up, or expired. Of the remaining 25 patients, 9 were retreated with the combination of platinum/bevacizumab (PB), 6 were retreated with a platinum regimen without bevacizumab (P), and 10 were retreated with neither (not-P). The only long-term survivor was in the not-P group and was treated with an immunotherapy agent. Median overall survival of all patients was 7.1months. There was a marginal difference in survival between women in the PB and not-PB groups (11.8 versus 5.7months; HR 3.02, 95% CI, 0.98–9.28). There was no difference in survival based on platinum interval (HR 0.81; 95% CI, 0.27–2.45). Outcomes are grim for women retreated after platinum/bevacizumab therapy and are only marginally improved by retreatment with a platinum/bevacizumab regimen. Rather than additional PB therapy, women with cervical cancer who recur after platinum/bevacizumab should consider supportive care or clinical trials. Highlights ? Repeating platinum/bevacizumab chemotherapy is associated with a marginal survival benefit. ? We discerned no survival difference based on platinum-free interval and chemotherapy utilized. ? Consider supportive care or clinical trial in patients with disease after platinum/bevacizumab.
机译：我们的目标是评估先前接受铂/贝伐单抗化疗后宫颈癌患者的整体生存率，将铂/贝伐单抗的再治疗与其他疗法进行比较。对2005年7月1日至2015年12月在华盛顿大学接受铂/贝伐单抗（PB）化疗治疗宫颈癌的妇女进行了回顾性分析。Wilcoxon秩和精确检验和Fisher精确检验用于比较治疗组，并生成Kaplan Meier曲线。进行Cox回归分析，将无治疗间隔和既往治疗反应作为协变量。在接受PB化疗的84例患者中，有59例（70％）未接受二线化疗，因为它们没有复发，未经进一步化疗而进展，失去随访或已过期。其余25例患者中，有9例接受铂/贝伐单抗（PB）联合治疗，6例接受无贝伐单抗（P）的铂类药物治疗，而10例均不接受任何贝伐单抗（P）治疗。唯一的长期幸存者是非P组，并接受了免疫治疗剂治疗。所有患者的中位总生存时间为7.1个月。 PB组和非PB组的女性生存率差异很小（11.8个月与5.7个月; HR 3.02，95％CI，0.98-9.28）。根据铂金间隔，生存率无差异（HR 0.81; 95％CI，0.27–2.45）。对于接受铂/贝伐单抗治疗后再入院的妇女而言，其治疗结果是严峻的，并且仅通过铂/贝伐单抗治疗重新治疗才略有改善。在铂/贝伐单抗治疗后复发的宫颈癌女性，而不是额外的PB疗法，应考虑支持治疗或临床试验。强调 ？重复铂/贝伐单抗化疗与生存率降低相关。 ？基于无铂间隔和使用的化疗，我们没有发现生存差异。 ？在铂/贝伐单抗治疗后的疾病患者中考虑支持治疗或临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号